BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 26, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AD01: Phase I data

In an Austrian Phase I trial in 24 patients with mild to moderate AD, AD01 met the primary safety endpoints with no serious side effects associated with the vaccine over 1...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >